NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”) a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases today announced the appointment of Dr. Vern Lee Schramm to the Board of Directors effective October 10, 2017.
Dr. Schramm has served as Professor of the Albert Einstein College of Medicine since 1987. Dr. Schramm served as the Chairman of the Department of Chemistry at the Albert Einstein College of Medicine from 1987 to 2015. He has been awarded the Ruth Merns Endowed Chair of Biochemistry. His fields of interest include enzymatic transition state analysis, transition state inhibitor design, biological targets for inhibitor design, and mechanisms of N-ribosyltransferases. Dr. Schramm was elected to the National Academy of Sciences in 2007, and served as the Associate Editor for the Journal of the American Chemical Society from 2003 to 2012. A frequent lecturer and presenter in topics related to chemical biology, Dr. Schramm has been a consultant and advisor to Pico Pharmaceuticals, Metabalon Biochemistry, Sirtris Scientific, and BioCryst Pharmaceuticals.
Dr. Schramm obtained his BS in Bacteriology with an emphasis in chemistry from South Dakota State College, a Master’s Degree in Nutrition with an emphasis in biochemistry from Harvard University, and a Ph.D. in Mechanism of Enzyme Action, Department of Biochemistry, from Australian National University.
"I am delighted to welcome Dr. Schramm to the AzurRx Board," said Thijs Spoor, CEO of AzurRx BioPharma. "Vern’s substantial experience at the leading edge of biochemistry and knowledge of the chemistry related to non-systemic biologics will assist the company in developing our portfolio of drug candidates."
"I am pleased to be working with the AzurRx team," said Dr. Schramm, "and look forward to using my experience to help it further develop its GI and infectious disease therapeutic portfolio."
About AzurRx BioPharma, Inc.
AzurRx BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infection. The company is headquartered in New York, NY, with scientific operations based in Langlade, France.
Company website address: www.azurrx.com
This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Additional information concerning the Company and its business, including factors that potentially could materially affect the Company’s financial results, are contained in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
For more Information:
AzurRx BioPharma, Inc.,
760 Parkside Avenue
Brooklyn, NY 11226
Phone: (646) 699-7855
Source:AzurRx BioPharma, Inc.